BSLN — Basilea Pharmaceutica AG, Allschwil Share News
0.000.00%
Last trade - 00:00- CH₣888.06m
- CH₣785.65m
- CH₣232.38m
European stocks rise ahead of inflation data; Basilea shines
Swiss stocks - Factors to watch on April 4
US FDA approves Basilea Pharmaceutica's antibiotic (updated)
Brief: FDA Approves New Antibiotic For Three Different Uses
US FDA approves Basilea Pharmaceutica's antibiotic
Brief: Basilea Pharmaceutica FY Operating Income CHF 19.2 Million
Brief: Basilea Announces That FDA Approves Expanded Use Of Antifungal Cresemba® (Isavuconazole) In The United States In Children With Invasive Aspergillosis And Invasive Mucormycosis
Swiss stocks - Factors to watch on September 28
Newer antibiotic effective against deadly staph infection in trial
Brief: Basilea Says H1 2023 Total Revenue Of CHF 84.9 Mln Vs CHF 57.6 Mln
Europe Research Roundup: Biomerieux, Dormakaba Holding AG, HSBC
Brief: Basilea Provides Update On New Drug Application To The US FDA For Antibiotic Ceftobiprole
Brief: Basilea Reports FY 2022 Total Revenue Of CHF 147.8 Mln
Brief: Basilea: Prelim Operating Profit For 2022 Significantly Above Guidance
Brief: Basilea: Continued Strong Cresemba Sales By Astellas In U.S. Trigger CHF 20 Mln Sales Milestone Payment To Basilea
Swiss stocks - Factors to watch on December 28
Brief: Basilea: Annouces Sale Of Preclinical Oncology Program To Twentyeight-Seven Therapeutics
Swiss stocks - Factors to watch on September 21
Brief: Basilea Reports Acquisition Of Rights For Oncology Asset BAL0891 By Sillajen; Updates Financial Guidance